ZM008

· Zumutor Biologics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ZM008, covering 2026-04-02 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors [Phase 1]

See pricing